Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of remimazolam on reversal of rocuronium-induced neuromuscular blockade with sugammadex
jRCT1071230073Recruiting
- Start
- Oct 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Trial of remimazolam, rocuronium and Sugammadex. Primary endpoint: Time from sugammadex administration to TOF ratio ≥0.90. Started Oct 2023; status: recruiting.
02
Drugs
remimazolamrocuroniumSugammadex
Beyond the preview
Go deeper on jRCT1071230073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071230073.